HemaCare (OTCMKTS:HEMA) Shares Up 0.6% – Still a Buy?

HemaCare Co. (OTCMKTS:HEMA) shares were up 0.6% during trading on Wednesday . The stock traded as high as $25.31 and last traded at $25.31. Approximately 5,400 shares traded hands during trading, a decline of 86% from the average daily volume of 39,950 shares. The stock had previously closed at $25.16.

HemaCare Stock Performance

The business has a 50-day moving average price of $25.31 and a 200-day moving average price of $25.31.

HemaCare Company Profile

HemaCare Corporation is a specialty life sciences company that supplies primary human blood and bone marrow-derived cells for research, drug development and medical device evaluation. The company’s product portfolio includes peripheral blood mononuclear cells (PBMCs), buffy coats, hematopoietic stem and progenitor cells, whole blood, bone marrow aspirates and custom-processed cell fractions. These offerings are designed to support preclinical studies, translational research and in vitro assays across immunology, hematology, oncology and regenerative medicine applications.

In addition to off-the-shelf cell products, HemaCare provides custom cell isolation services, donor screening and logistics solutions tailored to the needs of pharmaceutical, biotechnology and academic customers.